Given the elevated lifetime risk, many female BRCA1/2 and PALB2 germline pathogenic variant carriers (herein referred to as “carriers”) may wish to consider risk-reducing mastectomy (RRM) in order to prevent the development of breast cancer [1]. Here, PALB2 is linked to breast carcinoma.